#vrtx

-병을 일으키는 유전자를 찾아내 그 유전자를 변형시키는 치료제를 만드는 바이오기업

- 낭포성 섬유증 치료제를 개발하여 90%의 환자의 증상을 완화시킴. 나머지 10% 환자에 대하여 모더나와 협력하여 치료제 개발중

- 특허만료기간도 아직 5~10년정도 남아있음.

Vertex Pharmaceuticals (VRTX): Q3 2019 Earnings Snapshot

— Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected

— Total revenue grew 21% to $949.8 million, vs $950.9 million expected.

— Reiterated FY19 product revenues guidance of $3.70 – 3.75 billion. Non-GAAP effective tax rate outlook was also unchanged at 21-22%.

— VRTX shares were down 0.14% immediately following the…

Motley Fool: 3 Stocks That Could Double Your Money

Doubling your money isn’t as difficult as it might seem. You just need the right stocks and enough time. I’m not talking about 50 years. There are plenty of stocks with the potential to at least double in five years or less.

Three stocks that I think could double your money in a relatively short time frame are Guardant Health (NASDAQ:GH), The Trade Desk (NASDAQ:TTD), and Vertex Pharmaceuticals (

Motley Fool: 5 Things You Need to Know From Vertex Pharmaceuticals’ Q1 Earnings Update

Quarterly updates just look too easy for Vertex Pharmaceuticals (NASDAQ:VRTX). The biotech announced its first-quarter earnings results on Tuesday. Yet again, Vertex posted strong revenue and earnings growth that blew past Wall Street analysts’ estimates.

Vertex’s management team fielded questions from analysts during the company’s Q1 conference callTuesday evening. Here are five things you…

Vertex Pharmaceuticals (VRTX) to report Q1 2019 earnings today

Vertex Pharmaceuticals (NASDAQ: VRTX) is set to post first quarter 2019 earnings results today after the closing bell. Analysts expect the company to report earnings of $0.98 per share on revenue of $843.8 million.

In the fourth quarter of 2018, Vertex reported total revenue of $870 million. GAAP EPS amounted to $5.97, helped by income tax benefits, while adjusted EPS totaled $1.30.

For the full…